scholarly journals Influence of body size on platelet response to ticagrelor and prasugrel in patients with acute coronary syndromes

2021 ◽  
Author(s):  
Gjin Ndrepepa ◽  
Stefan Holdenrieder ◽  
Isabell Bernlochner ◽  
Adnan Kastrati
Keyword(s):  
Body Size ◽  
Acute Coronary Syndromes ◽  
Platelet Response ◽  
Coronary Syndromes

Near patient anti-platelet response testing over time and gene analysis in patients admitted with acute coronary syndromes

Platelets ◽  
2012 ◽  
Vol 24 (8) ◽  
pp. 643-648 ◽  
Author(s):  
Vincent Amoah ◽  
Robert F. Storey ◽  
Andrew P. Worrall ◽  
Kevin Goodridge ◽  
Tracy Lovatt ◽  
...  
Keyword(s):  
Acute Coronary Syndromes ◽  
Gene Analysis ◽  
Platelet Response ◽  
Coronary Syndromes ◽  
Response Testing ◽  
Over Time

Importance of platelets and platelet response in acute coronary syndromes

2009 ◽  
Vol 76 (4 suppl 1) ◽  
pp. S2-S7 ◽  
Author(s):  
Deepak L. Bhatt ◽  
W. Frank Peacock ◽  
Kandice Kottke-Marchant
Keyword(s):  
Acute Coronary Syndromes ◽  
Platelet Response ◽  
Coronary Syndromes

scholarly journals The Impact of CYP2C19 Loss-of-Function Polymorphisms, Clinical, and Demographic Variables on Platelet Response to Clopidogrel Evaluated Using Impedance Aggregometry

2016 ◽  
Vol 23 (3) ◽  
pp. 255-265 ◽  
Author(s):  
Alina Mărginean ◽  
Claudia Bănescu ◽  
Valeriu Moldovan ◽  
Alina Scridon ◽  
Mihai Mărginean ◽  
...  
Keyword(s):  
Acute Coronary Syndromes ◽  
European Population ◽  
Demographic Variables ◽  
Loss Of Function ◽  
Platelet Response ◽  
East European ◽  
Impedance Aggregometry ◽  
Coronary Syndromes ◽  
The Impact ◽  
Cyp2c19 Polymorphisms

Introduction: Clopidogrel is an antiplatelet drug widely used in patients with acute coronary syndromes or stroke. Despite adequate antiplatelet therapy, some patients develop acute ischemic events. This is partly attributed to the fact that they have poor inhibition of platelet reactivity, despite treatment. This study aimed to assess the impact of clinical and demographic variables and of cytochrome P450 2C19 (CYP2C19) loss-of-function polymorphisms on platelet response to clopidogrel evaluated using impedance aggregometry in an East European population. Methods: The study included 189 clopidogrel-treated patients with acute coronary syndromes and noncardiogenic ischemic stroke. Platelet aggregation was evaluated by impedance aggregometry. CYP2C19 loss-of-function polymorphisms were detected using the polymerase chain reaction restriction fragment length polymorphism technique. Various clinical and demographic data were also recorded. Results: In our data set, 81% of the patients were responders and 19% nonresponders to clopidogrel therapy. The distribution of CYP2C19 polymorphisms was as follows: 61.1% of patients were CYP2C19 wild-type homozygotes, 27.7% of patients were CYP2C19*2 heterozygotes, 1.1% of patients were CYP2C19*3 heterozygotes, and 10% of patients were CYP2C19*2 homozygotes. The highest level of association with clopidogrel response status was found for CYP2C19 polymorphisms, concomitant aspirin treatment, leukocyte and platelet count, history of myocardial infarction, arterial hypertension, and ward where patients were admitted. Conclusion: The prevalence of clopidogrel resistance in our East European population was in line with that reported for Western populations. Clopidogrel response was significantly influenced by the presence of CYP2C19 polymorphisms. Interestingly, the concomitant use of aspirin had a significant impact on platelet response to clopidogrel, indicating a synergic interaction between these drugs.

Sign in / Sign up

Export Citation Format

Share Document